Market Context — Why This Technology, Why Now

The global healthcare landscape is rapidly shifting towards preventative care and remote monitoring, driven by escalating medical costs and a growing demand for patient-centric solutions. Wearable health technology and digital diagnostics are experiencing exponential growth, with consumers actively seeking tools for self-monitoring. This technology aligns perfectly with these trends, offering a critical diagnostic capability that can be integrated into existing and new digital health platforms, enhancing competitive differentiation and addressing a major public health challenge.

Key Competitive Advantages
01

Enables non-invasive, high-accuracy AFib detection using existing pulse sensors

02

Reduces the risk of missing paroxysmal AFib by capturing subtle signs

03

Secures a robust patent, having overcome 6 prior art rejections, ensuring high reliability

Market Opportunity
Digital Health & Wearable Devices
$1B–$1.5B globally (AI est.)
Rising health consciousness and technological integration are rapidly increasing demand for daily health management.
Major consumer electronics brands Digital health platform providers Wearable device manufacturers
Telemedicine & Home Monitoring
$0.5B–$1B globally (AI est.)
Disparities in medical resources and an aging population are expanding the need for home-based medical services.
Telehealth service providers Home healthcare equipment suppliers Remote patient monitoring solution developers
Preventative Healthcare Services
$500M–$650M globally (AI est.)
Early detection and intervention for diseases contribute to healthcare cost reduction and extension of healthy life expectancy.
Corporate wellness program providers Health insurance companies Preventative health clinic networks
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects a pulse wave signal analysis device, method, and program, specifically covering a unique Fourier transform technique that shifts analysis frames by 0.005-0.02 seconds to detect atrial fibrillation. Its broad claims and successful navigation through examiner rejections against six prior art documents indicate a robust and stable intellectual property with low invalidation risk.

Competitive White Space

This patent primarily covers AFib detection via pulse wave analysis. White space exists in integrating this technology with other biometric data streams for comprehensive health assessments or developing predictive analytics for broader cardiovascular risk factors beyond AFib.

Economic Impact
~$1M/year estimated healthcare cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Early detection of atrial fibrillation patients could reduce the risk of severe complications like cerebral infarction, leading to an estimated average annual healthcare cost reduction of ~$6.5K per patient (AI est.). If 150 new patients are detected early per year, this could result in an annual healthcare cost reduction of ~$1M (AI est.).

Speed to Market
5× faster than in-house development
Developing a similar AFib detection technology from scratch, including basic research, algorithm development, clinical validation, and regulatory approval, is estimated to take approximately 4.0 years. By licensing this patent, companies can leverage already validated technical principles and an established Fourier transform-based analysis algorithm, shortening development time by about 3.2 years. Integration into existing pulse wave sensors and wearable devices is relatively straightforward, enabling rapid market entry and competitive advantage.
Competitive Positioning

X: Detection Accuracy & Reliability
Y: Ease of Implementation & Non-Invasiveness

Business Models & Applications
🏥 Licensing to Medical Device Manufacturers
License this technology for integration into existing blood pressure monitors or smartwatches. This supports the development of high-value-added new products and generates royalty revenue.
🌐 Remote Monitoring Service
Offer a pulse wave analysis cloud service utilizing this technology. This subscription model continuously monitors patient data and notifies medical institutions of abnormalities.
📊 Data Analysis Platform
Accumulate anonymized pulse wave data and analysis results. Provide this big data to research institutions and pharmaceutical companies to contribute to new treatment development and drug discovery.
Adjacent Application Opportunities
🏥 医療機関
Outpatient & Ward Screening
Integrate this technology into routine pulse wave measurements for hospital outpatients and wards. It could efficiently identify patients at risk of AFib, allowing for early intervention. This would support physician diagnosis and potentially reduce patient waiting times.
🏠 在宅介護
Elderly Home Monitoring Device Integration
Integrate this technology into monitoring devices for elderly individuals receiving home care. Continuous pulse wave measurement during daily activities and sleep could detect AFib signs, sending alerts to caregivers, family, or medical institutions for early emergency response.
🏃‍♂️ フィットネス・健康管理
Exercise Cardiac Risk Monitoring
Utilize this technology in simple devices to measure pulse waves before and after exercise in fitness centers. Monitoring cardiac strain and potential AFib risks during physical activity could support safe exercise guidance and health management, promoting user well-being and preventing accidents.
Integration Roadmap — Estimated 27-Month Deployment
Technology Validation & PoC
Duration: 6 months
Evaluate the technology's compatibility with the licensee's existing devices and systems. Verify concrete implementation effects and feasibility through a Proof of Concept (PoC).
Prototype Development & Integration
Duration: 12 months
Develop a prototype incorporating the technology's analysis module based on validation results. Integrate with existing data collection systems and UI, making adjustments for practical operation.
Demonstration & Market Readiness
Duration: 9 months
Conduct demonstration experiments with the developed prototype to confirm accuracy and stability. Prepare for regulatory applications and formulate marketing strategies, completing final preparations for market launch.
Technical Feasibility
This technology is software-centric, utilizing generic non-invasive pulse wave sensors (e.g., photoplethysmography sensors) to detect biological pulse signals and analyze them with a proprietary Fourier transform algorithm. It can be implemented by integrating the patented analysis program into existing hardware like wearable devices or blood pressure monitors. No significant new capital investment or complex physical interface changes are required, making its technical feasibility extremely high, akin to a software update.
Success Scenario
Upon adoption, companies could integrate early atrial fibrillation detection capabilities into existing products such as home blood pressure monitors or smartwatches. This would allow users to routinely monitor their heart condition and identify abnormal signs early. Consequently, it is estimated that this could significantly reduce the risk of severe complications like cerebral infarction caused by AFib, contribute to national healthcare cost reduction, and improve patient quality of life.
Patent Record
APPLICATION NO.
特願2020-530018
REGISTRATION NO.
7327816
FILING DATE
2019/05/24
GRANT DATE
2023/08/07
EXPIRATION DATE
2039/05/24
PATENT HOLDER
国立大学法人　香川大学
Examination History
2021年02月01日
国際予備審査報告（英語）
2022年03月16日
出願審査請求書
2023年03月07日
拒絶理由通知書
2023年04月28日
手続補正書（自発・内容）
2023年04月28日
意見書
2023年07月18日
特許査定